Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding

• Status: Not yet recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Acute Variceal Bleeding (AVB) in patients with liver cirrhosis is a common clinical critical disease.There is little evidence for the effect of PPI use in patients with AVB in liver cirrhosis, and there is no study on the efficacy of PPI combined with standard therapy in patients with AVB.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: West China Hospital
• Treatments: Esomeprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole

Criteria

Inclusion Criteria:

1. Liver cirrhosis.

2. The etiology of portal hypertension is cirrhosis.

3. Patients presenting with acute esophageal variceal bleeding proven by emergency endoscopy within 24 hours.

4. Be willing to participate in this clinical study, comply with the study requirements and sign the informed consent

Exclusion Criteria:

1. non-cirrhotic portal hypertension

2. the time from admission to endoscopy was more than 24 hours

3. patients with peptic ulcer or gastroesophageal reflux disease requiring PPI therapy

4. PPI use for more than 2 weeks before admission

5. received endoscopic or interventional therapy within the previous 4 weeks

6. PPI allergy

7. Chronic renal insufficiency (CKD stage 3-5)

8. Severe cardiopulmonary dysfunction (such as heart failure grade 3-4, respiratory failure, etc.)

9. Hepatocellular carcinoma (Barcelona Clinic Liver Cancer (BCLC) stage C and D)

10. other advanced malignancies (life expectancy less than 6 months)

11. Pregnancy